Literature DB >> 9309115

p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis.

L Stuppia1, G Calabrese, R Peila, P Guanciali-Franchi, E Morizio, A Spadano, G Palka.   

Abstract

A longitudinal investigation using fluorescence in situ hybridization (FISH) analysis, PCR-SSCP, and in situ detection of apoptosis by the terminal deoxynucleotidyl Transferase (TdT) method was carried out on 13 chronic myelogenous leukemia (CML) patients to study the p53 gene behavior and the apoptotic process during the course of the disease. At diagnosis, FISH showed no loss of the p53 gene on interphase nuclei, and no point mutation was detected by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and sequencing. During the disease course, FISH analysis showed a significative loss of allele (LOA) rate for the p53 gene in eight patients that in seven cases was associated with a suppression of apoptotic process and the progressive expansion of the p53+/p53- clone. DNA sequencing showed in two of these eight patients a point mutation on the other allele, consisting in the formation of a stop codon in one case, and in a frameshift mutation in the other. Six patients had a myeloid blastic crisis (BC), five a lymphoid BC, and the other two an erythroid and an undifferentiated BC, respectively. All patients with myeloid BC and the one with undifferentiated BC disclosed a progressive expansion of the clone with p53 loss that was associated with a significant reduction in apoptosis. On the contrary in the 5 patients with lymphoid BC no significant p53 LOA rate was observed during the course of the disease. In these patients apoptotic process also persisted in the acute phase although in a lower rate as compared to CP.

Entities:  

Mesh:

Year:  1997        PMID: 9309115     DOI: 10.1016/s0165-4608(96)00413-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells.

Authors:  I Unnikrishnan; A Radfar; J Jenab-Wolcott; N Rosenberg
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 4.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 5.  Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients.

Authors:  Lulu Wang; Li Li; Rongrong Chen; Xianbo Huang; Xiujin Ye
Journal:  Cancer Manag Res       Date:  2021-06-23       Impact factor: 3.989

6.  The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation.

Authors:  Muhammad Shahzad Ali; Stefano Magnati; Cristina Panuzzo; Daniela Cilloni; Giuseppe Saglio; Barbara Pergolizzi; Enrico Bracco
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.